An understanding that specific CR1 derivatives can act as anti-hemolytic agent to inhibit red cell hemolysis both in the test tube as well as in small animal models.
Karina Yazdanbakhsh, PhD

Generating novel red blood cell reagents from induced pluripotent stem cells engineered to express combinations of blood group antigens that are rare or never found, allowing for rapid identification of antibodies.
Stella T. Chou, MD

Identifying the SMM1 protein on the red blood cell membrane and confirming its absence or presence in red blood cells from Vel-negative and Vel-positive donors.
Jill R. Storry, PhD

Development of mouse models of acute and delayed HTRs that mimic the complications seen in humans following a blood transfusion.
Steven L. Spitalnik, MD

Confirming the reversibility of the platelet shape change during storage.
Paul D. Mintz, MD

Understanding the impact of the inflammatory status of transfusion recipients on RBC alloantibody formation.
Jeanne E. Hendrickson, MD

Development of a TRALI alternate pathophysiology and two-event model.
Christopher Silliman, MD, PhD

Fruitful collaborations with industry partners resulting in the development of diagnostic and blood screening assays, in addition to serving as a testing platform for pathogen inactivation strategies.
Cheryl Lobo, PhD